Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ASP-1929 + Cemiplimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ASP-1929||Cetuximab sarotalocan|Cetuximab-IRDye-700DX|RM-1929|Cet-IR700|ASP1929||EGFR Antibody 38||ASP1929 (RM-1929) is comprised of the EGFR antibody cetuximab conjugated to the dye IR700, which binds to EGFR-expressing cells and disrupts the cell membrane upon exposure to near-infared light (NCI Drug Dictionary).|
|Cemiplimab||Libtayo||REGN2810|SAR439684||Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83||Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation, in patients with locally advanced or metastatic basal cell carcinoma who have received or are not eligible for a hedgehog pathway inhibitor, and as first-line treatment in patients with advanced non-small cell lung cancer with high PD-L1 expression (TPS>=50%) and no EGFR, ALK, or ROS1 aberrations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04305795||Phase Ib/II||ASP-1929 + Pembrolizumab ASP-1929 + Cemiplimab||An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors||Recruiting||USA||0|